MPLT
HealthcareMapLight Therapeutics, Inc.
$17.22
+$0.45 (+2.68%)
Jan 5, 2026
Price History (1Y)
Analysis
MapLight Therapeutics, Inc. is a biotechnology company operating in the healthcare sector. With a market capitalization of $781.32 million and approximately 114 employees, it represents a notable entity within its industry. The company's financial health suggests significant losses, with net income totaling -$102,833,000 and EBITDA at -$107,851,000 over the trailing twelve months. Margins are also minimal, with gross margin, operating margin, and profit margin all registering 0.0%. The balance sheet presents a relatively low debt-to-equity ratio of 2.57, while cash reserves amount to $227.17 million against a minor debt of $6.01 million. Valuation metrics for MapLight Therapeutics, Inc. indicate unfavorable readings, with price-to-book and EV/EBITDA ratios at -38.27 and -97.34, respectively. These figures suggest that the company's stock is significantly discounted relative to its book value and earnings.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. MapLight Therapeutics, Inc. was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California.
Visit website →Key Statistics
- Market Cap
- $781.32M
- P/E Ratio
- N/A
- 52-Week High
- $21.55
- 52-Week Low
- $12.24
- Avg Volume
- 392.80K
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 114